학술논문
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study
Document Type
Article
Author
Johnson, P.J.; Qin, S.; Xu, J.; Lu, L.; Yan, L.; Poon, R.T.P.; Park, J.-W.; Heo, J.; Han, K.-H.; Paik, S.-W.; Tak, W.-Y.; Raoul, J.-L.; Boucher, E.; Decaens, T.; Philip, P.A.; Liu, D.; Ezzeddine, R.; Walters, I.; Hsu, C.-H.; Cheng, A.-L.; Chao, Y.; Hu, T.-H.; Jeng, L.-B.; Robles-Aviña, J.; Kudo, M.; Sobhonslidsuk, A.; Komov, D.
Source
In: Journal of Clinical Oncology . (Journal of Clinical Oncology, 1 October 2013, 31(28):3517-3524)
Subject
Language
English
ISSN
15277755
0732183X
0732183X